A look back at the week's news.
Teenaged girls at average risk don’t need Papanicolaou tests, but some special populations do.
Best practices on discussing birth control for adolescents.
If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).
Check out these latest resources from the American Urogynecologic Society.
Changes for ICD-10 documentation codes that go into effect in October 2022.
Tips to avoid wasting time and optimize meetings you do need.
Inactivated COVID-19 vaccines in pregnancy: No impact on neonatal outcome, study finds
November 28th 2023A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Read More
A closer look at women's concerns on breast density in clinician discussions
November 27th 2023A study found variations in discussions about breast density based on race and ethnicity, leading researchers to urge enhanced cultural competency and shared decision-making to bridge critical gaps in breast density conversations.
Read More
High rates of perinatal anxiety in women from low- and middle-income countries
November 24th 2023A recent comprehensive study reveals that 1 in 5 women in low- and middle-income countries grapple with perinatal anxiety disorders, shedding light on a critical yet often overlooked mental health challenge affecting maternal and infant outcomes in these regions.
Read More